patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_836840 | REC_0003001 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 19.2 | 61 | female | 1 | 18 | 5 | 2 | pembrolizumab 200 mg q3w | 16.1 | false | MSI-H | 2026-03-15T05:35:57.584508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686111 | REC_0003002 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 2.1 | 62 | male | 0 | 8 | 4.4 | 2 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.584744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468222 | REC_0003003 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 6.9 | 59 | female | 1 | 10 | 4.6 | 3 | osimertinib 80 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:57.584976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770563 | REC_0003004 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15.9 | 71 | female | 2 | 13 | 7.3 | 7 | osimertinib 80 mg daily | 10 | true | MSI-H | 2026-03-15T05:35:57.585305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966613 | REC_0003005 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 11.6 | 60 | male | 1 | 12 | 6.5 | 1 | osimertinib 80 mg daily | 19.6 | true | MSS | 2026-03-15T05:35:57.585550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792296 | REC_0003006 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 9 | 71 | male | 2 | 13 | 7.1 | 2 | sotorasib 960 mg daily | 27.8 | false | MSS | 2026-03-15T05:35:57.585784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830837 | REC_0003007 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.3 | 66 | female | 0 | 27 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.1 | true | MSS | 2026-03-15T05:35:57.586014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906762 | REC_0003008 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.8 | 49 | female | 0 | 21 | 4.5 | 3 | entrectinib 600 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:57.586252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848772 | REC_0003009 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.6 | 74 | female | 1 | 23 | 5.2 | 5 | pembrolizumab 200 mg q3w | 6.1 | false | MSS | 2026-03-15T05:35:57.586481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123696 | REC_0003010 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 11.4 | 53 | female | 0 | 10 | 8.8 | 6 | osimertinib 80 mg daily | 4.9 | false | MSS | 2026-03-15T05:35:57.586719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456846 | REC_0003011 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 6.1 | 53 | male | 0 | 17 | 7.5 | 0 | osimertinib 80 mg daily | 23 | false | MSS | 2026-03-15T05:35:57.586951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854151 | REC_0003012 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 8.4 | 62 | male | 0 | 10 | 6.7 | 1 | alectinib 600 mg BID | 16.2 | true | MSS | 2026-03-15T05:35:57.587183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462501 | REC_0003013 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 13.6 | 64 | male | 1 | 13 | 5.7 | 2 | alectinib 600 mg BID | 21.8 | true | MSI-H | 2026-03-15T05:35:57.587417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480149 | REC_0003014 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 12.1 | 45 | female | 0 | 12 | 7.4 | 6 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:57.587652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229708 | REC_0003015 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.3 | 63 | male | 0 | 30 | 6.5 | 5 | osimertinib 80 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:57.587884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609671 | REC_0003016 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 16.4 | 60 | female | 0 | 13 | 6.7 | 1 | sotorasib 960 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:35:57.588153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563773 | REC_0003017 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 8.1 | 73 | female | 1 | 12 | 6.9 | 2 | alectinib 600 mg BID | 24.2 | true | MSS | 2026-03-15T05:35:57.588445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409303 | REC_0003018 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 17.3 | 67 | male | 0 | 23 | 4.9 | 4 | alectinib 600 mg BID | 9 | true | MSS | 2026-03-15T05:35:57.588688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249513 | REC_0003019 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 17.3 | 55 | male | 1 | 15 | 5.6 | 4 | osimertinib 80 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:57.588924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833849 | REC_0003020 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 14 | 3.2 | 56 | female | 1 | 17 | 4.6 | 2 | pembrolizumab 200 mg q3w | 13.7 | true | MSS | 2026-03-15T05:35:57.589158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592047 | REC_0003021 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 16.6 | 72 | female | 2 | 15 | 5.4 | 3 | entrectinib 600 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:57.589390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583463 | REC_0003022 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 7.3 | 73 | female | 2 | 6 | 7.3 | 1 | alectinib 600 mg BID | 9 | true | MSS | 2026-03-15T05:35:57.589621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864736 | REC_0003023 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10.3 | 69 | female | 1 | 13 | 6.3 | 2 | osimertinib 80 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:57.589852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993449 | REC_0003024 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 20 | 4.4 | 58 | male | 1 | 11 | 4.1 | 0 | pembrolizumab 200 mg q3w | 42.7 | true | MSS | 2026-03-15T05:35:57.590086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932139 | REC_0003025 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 18.3 | 53 | male | 0 | 20 | 4.4 | 4 | sotorasib 960 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:57.590320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407278 | REC_0003026 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 16.3 | 61 | female | 0 | 3 | 6 | 5 | alectinib 600 mg BID | 17.7 | false | MSI-H | 2026-03-15T05:35:57.590554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551981 | REC_0003027 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 6 | 63 | female | 0 | 13 | 6.6 | 2 | sotorasib 960 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:57.590787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556876 | REC_0003028 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 16 | 73 | female | 1 | 17 | 7.2 | 1 | osimertinib 80 mg daily | 22.1 | false | MSS | 2026-03-15T05:35:57.591018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495860 | REC_0003029 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 20 | 6.7 | 64 | male | 1 | 18 | 7.2 | 0 | pembrolizumab 200 mg q3w | 40.6 | true | MSS | 2026-03-15T05:35:57.591249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885109 | REC_0003030 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.3 | 76 | female | 3 | 10 | 6.9 | 4 | entrectinib 600 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:57.591529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658883 | REC_0003031 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14.7 | 74 | female | 2 | 14 | 5.5 | 2 | entrectinib 600 mg daily | 23.1 | true | MSI-H | 2026-03-15T05:35:57.591769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132180 | REC_0003032 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 14.9 | 66 | female | 0 | 18 | 7.1 | 3 | alectinib 600 mg BID | 11.4 | true | MSI-H | 2026-03-15T05:35:57.592003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934460 | REC_0003033 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.7 | 68 | female | 1 | 22 | 7.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 18.4 | true | MSS | 2026-03-15T05:35:57.592405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932937 | REC_0003034 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13 | 73 | female | 2 | 3 | 3.7 | 1 | osimertinib 80 mg daily | 26.3 | false | MSI-H | 2026-03-15T05:35:57.592665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958088 | REC_0003035 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 12 | 55 | female | 1 | 8 | 3 | 4 | entrectinib 600 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:57.592905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563218 | REC_0003036 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11 | 79 | male | 1 | 18 | 4.7 | 7 | sotorasib 960 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:57.593139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548133 | REC_0003037 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 16.4 | 47 | male | 0 | 18 | 6 | 4 | pembrolizumab 200 mg q3w | 16 | false | MSS | 2026-03-15T05:35:57.593374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878428 | REC_0003038 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 6.2 | 75 | female | 1 | 16 | 3.7 | 3 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:57.593605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907262 | REC_0003039 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 22.8 | 75 | female | 1 | 10 | 5.5 | 3 | osimertinib 80 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:35:57.593839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288399 | REC_0003040 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 7.1 | 68 | female | 0 | 44 | 4.5 | 2 | pembrolizumab 200 mg q3w | 18.5 | true | MSS | 2026-03-15T05:35:57.594067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539217 | REC_0003041 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 4.4 | 66 | female | 0 | 21 | 8 | 5 | sotorasib 960 mg daily | 5.3 | false | MSS | 2026-03-15T05:35:57.594301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548516 | REC_0003042 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 2.9 | 69 | male | 0 | 24 | 5.5 | 2 | entrectinib 600 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:57.594532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786583 | REC_0003043 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 8.5 | 63 | female | 0 | 10 | 5.3 | 4 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:57.594828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750147 | REC_0003044 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 8.5 | 59 | female | 1 | 13 | 5.5 | 1 | osimertinib 80 mg daily | 26.6 | false | MSS | 2026-03-15T05:35:57.595069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562660 | REC_0003045 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 15.8 | 75 | female | 1 | 15 | 4.1 | 5 | entrectinib 600 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.595302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161659 | REC_0003046 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 11.7 | 70 | female | 2 | 17 | 6.1 | 1 | sotorasib 960 mg daily | 27.7 | false | MSS | 2026-03-15T05:35:57.595539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380399 | REC_0003047 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 4.1 | 69 | female | 1 | 43 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 19.2 | false | MSS | 2026-03-15T05:35:57.595773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156377 | REC_0003048 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 25 | 5.5 | 73 | male | 2 | 70 | 6 | 0 | pembrolizumab 200 mg q3w | 48.5 | true | MSS | 2026-03-15T05:35:57.596009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701103 | REC_0003049 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 17.3 | 61 | male | 1 | 19 | 4.4 | 5 | entrectinib 600 mg daily | 5 | true | MSI-H | 2026-03-15T05:35:57.596425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709634 | REC_0003050 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.9 | 56 | male | 0 | 10 | 4.8 | 5 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:57.596726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638232 | REC_0003051 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 19 | 18.8 | 58 | male | 0 | 12 | 4.5 | 0 | pembrolizumab 200 mg q3w | 43.7 | false | MSI-H | 2026-03-15T05:35:57.597028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926899 | REC_0003052 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 7.3 | 62 | male | 1 | 13 | 3.4 | 8 | osimertinib 80 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:57.597284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819467 | REC_0003053 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.7 | 63 | male | 0 | 1 | 4.9 | 2 | alectinib 600 mg BID | 20.9 | false | MSS | 2026-03-15T05:35:57.597532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453321 | REC_0003054 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 8.2 | 66 | male | 1 | 10 | 4.8 | 6 | alectinib 600 mg BID | 7 | false | MSS | 2026-03-15T05:35:57.597775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151292 | REC_0003055 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 15.1 | 62 | female | 1 | 17 | 6.1 | 6 | sotorasib 960 mg daily | 5.4 | false | MSS | 2026-03-15T05:35:57.598020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810932 | REC_0003056 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 11 | 8.8 | 66 | female | 0 | 54 | 5.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 18.4 | true | MSS | 2026-03-15T05:35:57.598374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730345 | REC_0003057 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.1 | 69 | female | 0 | 27 | 7.5 | 1 | osimertinib 80 mg daily | 17.3 | false | MSS | 2026-03-15T05:35:57.598630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638026 | REC_0003058 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14 | 57 | female | 0 | 11 | 4.9 | 7 | entrectinib 600 mg daily | 14.5 | false | MSI-H | 2026-03-15T05:35:57.598868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343378 | REC_0003059 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8.7 | 62 | female | 0 | 18 | 4.8 | 3 | alectinib 600 mg BID | 13.6 | false | MSS | 2026-03-15T05:35:57.599102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540966 | REC_0003060 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.1 | 73 | female | 2 | 23 | 7.2 | 9 | osimertinib 80 mg daily | 5.1 | false | MSI-H | 2026-03-15T05:35:57.599335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882426 | REC_0003061 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 7.8 | 75 | female | 1 | 16 | 5.3 | 1 | alectinib 600 mg BID | 17.7 | true | MSS | 2026-03-15T05:35:57.599569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871837 | REC_0003062 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 3.5 | 72 | female | 3 | 7 | 3.9 | 2 | osimertinib 80 mg daily | 27.6 | true | MSS | 2026-03-15T05:35:57.599812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429481 | REC_0003063 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 13 | 7.5 | 70 | female | 3 | 15 | 6.1 | 5 | pembrolizumab 200 mg q3w | 13.1 | false | MSS | 2026-03-15T05:35:57.600056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603025 | REC_0003064 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 15.8 | 61 | male | 1 | 10 | 4.5 | 8 | sotorasib 960 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:57.600379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496108 | REC_0003065 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 5 | 45 | female | 0 | 9 | 5.9 | 5 | entrectinib 600 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:57.600621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560646 | REC_0003066 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 6.8 | 79 | male | 1 | 31 | 2.9 | 1 | pembrolizumab 200 mg q3w | 9.5 | true | MSS | 2026-03-15T05:35:57.600869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171067 | REC_0003067 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 13.2 | 63 | male | 0 | 17 | 7.5 | 0 | osimertinib 80 mg daily | 60.5 | false | MSI-H | 2026-03-15T05:35:57.601135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606546 | REC_0003068 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 12.5 | 63 | female | 1 | 12 | 5.9 | 1 | sotorasib 960 mg daily | 28 | true | MSI-H | 2026-03-15T05:35:57.601396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593890 | REC_0003069 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.8 | 70 | female | 1 | 68 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSS | 2026-03-15T05:35:57.601775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893513 | REC_0003070 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11 | 52 | male | 0 | 17 | 5.3 | 7 | sotorasib 960 mg daily | 9 | false | MSS | 2026-03-15T05:35:57.602045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885313 | REC_0003071 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 12.1 | 76 | female | 1 | 13 | 6.2 | 5 | entrectinib 600 mg daily | 17.7 | true | MSI-H | 2026-03-15T05:35:57.602285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430384 | REC_0003072 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 11.3 | 74 | male | 1 | 14 | 5.3 | 4 | entrectinib 600 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:57.602528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985868 | REC_0003073 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 10.2 | 59 | male | 0 | 16 | 6.5 | 4 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:35:57.602768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624536 | REC_0003074 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.3 | 62 | female | 1 | 10 | 5.9 | 6 | entrectinib 600 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:57.603007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524278 | REC_0003075 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 13.8 | 60 | male | 1 | 12 | 7.2 | 0 | osimertinib 80 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:35:57.603245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949462 | REC_0003076 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 12.2 | 66 | female | 1 | 23 | 7.2 | 2 | sotorasib 960 mg daily | 17.9 | false | MSS | 2026-03-15T05:35:57.603485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269199 | REC_0003077 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 7.1 | 71 | male | 2 | 18 | 5.6 | 2 | osimertinib 80 mg daily | 17.6 | true | MSS | 2026-03-15T05:35:57.603720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622005 | REC_0003078 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8.3 | 72 | female | 1 | 14 | 4.8 | 7 | alectinib 600 mg BID | 11.1 | false | MSS | 2026-03-15T05:35:57.603954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933888 | REC_0003079 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 6.2 | 68 | female | 0 | 18 | 5.2 | 2 | sotorasib 960 mg daily | 24.6 | false | MSS | 2026-03-15T05:35:57.604270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512714 | REC_0003080 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 4.9 | 61 | female | 0 | 24 | 6.6 | 5 | pembrolizumab 200 mg q3w | 12.8 | true | MSS | 2026-03-15T05:35:57.604525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657624 | REC_0003081 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 6 | 77 | female | 2 | 59 | 4.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 25.7 | true | MSS | 2026-03-15T05:35:57.604766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877149 | REC_0003082 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 5.5 | 63 | male | 1 | 16 | 7.4 | 0 | sotorasib 960 mg daily | 38.9 | true | MSS | 2026-03-15T05:35:57.605109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676979 | REC_0003083 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.7 | 75 | female | 2 | 22 | 4.2 | 5 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:57.605354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331495 | REC_0003084 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 11.2 | 60 | male | 1 | 17 | 4.3 | 2 | osimertinib 80 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:57.605590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787929 | REC_0003085 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 15.9 | 76 | female | 2 | 14 | 5.7 | 5 | alectinib 600 mg BID | 13.8 | false | MSI-H | 2026-03-15T05:35:57.605828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807163 | REC_0003086 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.8 | 69 | female | 0 | 12 | 4.6 | 6 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.606063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494934 | REC_0003087 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7.5 | 51 | female | 0 | 9 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSS | 2026-03-15T05:35:57.606295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733032 | REC_0003088 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 12.5 | 64 | male | 0 | 11 | 4.7 | 0 | entrectinib 600 mg daily | 47.8 | false | MSI-H | 2026-03-15T05:35:57.606530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309169 | REC_0003089 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 14.2 | 73 | male | 3 | 3 | 6.5 | 1 | alectinib 600 mg BID | 17.9 | true | MSS | 2026-03-15T05:35:57.606768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904774 | REC_0003090 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.6 | 75 | male | 1 | 19 | 5.9 | 8 | entrectinib 600 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:57.607001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613449 | REC_0003091 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.7 | 70 | female | 2 | 19 | 4 | 4 | osimertinib 80 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:57.607235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413830 | REC_0003092 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 16 | 67 | female | 0 | 19 | 5 | 7 | sotorasib 960 mg daily | 8 | true | MSS | 2026-03-15T05:35:57.607468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883422 | REC_0003093 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 15.5 | 72 | female | 3 | 17 | 5.9 | 8 | sotorasib 960 mg daily | 19.2 | false | MSI-H | 2026-03-15T05:35:57.607698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675014 | REC_0003094 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 14.2 | 53 | female | 0 | 11 | 7.2 | 8 | sotorasib 960 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:57.607931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632071 | REC_0003095 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.9 | 52 | male | 0 | 9 | 6.4 | 5 | alectinib 600 mg BID | 6.9 | false | MSI-H | 2026-03-15T05:35:57.608272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127486 | REC_0003096 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 5 | 64 | male | 1 | 8 | 4.6 | 8 | entrectinib 600 mg daily | 15.1 | true | MSS | 2026-03-15T05:35:57.608517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743376 | REC_0003097 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 17.5 | 68 | female | 0 | 16 | 6.5 | 5 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.608756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519161 | REC_0003098 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 13 | 13 | 67 | female | 1 | 0 | 5.9 | 1 | entrectinib 600 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:35:57.608986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888297 | REC_0003099 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.8 | 70 | female | 2 | 48 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.1 | false | MSS | 2026-03-15T05:35:57.609215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687765 | REC_0003100 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 10.1 | 74 | female | 3 | 12 | 5.4 | 2 | entrectinib 600 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:57.609448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.